Aspergillosis clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for

  • Olorofim Aspergillus Infection Study

    open to eligible people ages 18 years and up

    The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

    San Francisco, California and other locations

  • Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

    Sorry, in progress, not accepting new patients

    This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

    San Francisco, California and other locations

Last updated: